Drug Type TCR therapy |
Synonyms NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical + [1] |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 2 | CN | 08 Jul 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 23 Mar 2020 | |
Recurrent Non-Small Cell Lung Cancer | Discovery | CN | 21 Mar 2017 |
NCT04318964 (Pubmed) Manual | Phase 1 | 12 | TAEST16001+cyclophosphamide+fludarabine | (qxruhgxkai) = daeippdeqa txjbhbaelu (txfltfmdip ) View more | Positive | 15 Aug 2023 | |
NCT04318964 (ASCO2022) Manual | Phase 1 | 12 | cyclophosphamide+fludarabine+NY-ESO-1–specific TCR T-cells (TAEST16001) | (vdgohuzqut) = lbuqwotcgb afykzngcfv (ukgfhburmm ) View more | Positive | 02 Jun 2022 |